Back to search results

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

Abroad (travel likely)RecruitingPHASE2

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Honor Health Neurology - Bob Bove Neuroscience Institute, Scottsdale, Arizona, United States

  • University of California San Diego, La Jolla, California, United States

  • Sutter Health - California Pacific Medical Center Research Institute, San Francisco, California, United States

  • Mayo Clinic Jacksonville, Jacksonville, Florida, United States

  • Lange Neurology, New York, New York, United States

  • NEUROHK s.r.o., Hradec Králové, Czechia

  • Thomayer University Hospital - Fakultni Thomayerova nemocnice, Prague, Czechia

  • Charité Centrum für Neurologie, Neurochirurgie und Psychiatrie, Berlin, Germany

  • DIAKOVERE Henriettenstift - Klinik für Neurologie und Klinische Neurophysiologie, Hanover, Germany

  • Universitaetsklinikum Schleswig-Holstein, Lübeck, Germany

  • Michalski i Partnerzy Lekarze Spółka Partnerska, Krakow, Poland

  • SP ZOZ Szpital Uniwersytecki w Krakowie, Krakow, Poland

  • Centrum Medyczne NeuroProtect (NeuroProtect Medical Center), Warsaw, Poland

  • City Clinic Research, Warsaw, Poland

  • University Clinical Center of Serbia, Belgrade, Serbia

  • Hospital General Universitario Dr. Balmis de Alicante, Alicante, Spain

  • Barcelona Sea Hospital (Hospital Del Mar De Barcelona), Barcelona, Spain

  • Hospital Universitario Vall D Hebron, Barcelona, Spain

  • Hospital Universitario Ramon Y Cajal, Madrid, Spain

  • Hospital Regional Universitario De Malaga, Málaga, Spain

  • Hospital Universitario Virgen Del Rocio, Seville, Spain

View source on ClinicalTrials.gov(opens in a new tab)